Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CTSG | P08311 | 2/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 5/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8211973 | 0.89 | MEN1 (0.48) | KMT2AMEN1POLBCTSGCTRB1 | |
| SCHEMBL6504398 | 0.89 | MEN1 (0.48) | KMT2AMEN1POLBCTSGCTRB1 | |
| SCHEMBL29067682 | 0.88 | GAA (0.53) | KMT2AMEN1POLBCTSGCTRB1 | |
| SCHEMBL13868571 | 0.88 | GAA (0.53) | KMT2AMEN1POLBCTSGCTRB1 | |
| SCHEMBL4896289 | 0.88 | GAA (0.53) | KMT2AMEN1POLBCTSGCTRB1 | |
| SCHEMBL820939 | 0.86 | SMN1; SMN2 (0.49) | KMT2AMEN1POLBCTSSCTSK | |
| SCHEMBL5219235 | 0.85 | KMT2A (0.50) | KMT2AMEN1POLBCTSBALDH1A1 | |
| SCHEMBL7923262 | 0.85 | TP53 (0.45) | KMT2AMEN1GAAALDH1A1HPGD | |
| SCHEMBL6506417 | 0.85 | CTSL (0.50) | CTSLGAAALDH1A1RAB9AHPGD | |
| SCHEMBL10657225 | 0.85 | HTT (0.53) | KMT2AMEN1POLBGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1781915-A | Process for preparing oxazolylethanol derivatives | JAPAN TOBACCO INC (JP) | 2006-06-07 | — | — | CN | disclosed |
| US-6995271-B2 | Production method of isoxazolidinedione compound | JAPAN TOBACCO, INC. (JP) | 2006-02-07 | — | — | US | disclosed |
| CN-1235887-C | Process for preparing oxazolylethanol derivatives | JAPAN TOBACCO INC (JP) | 2006-01-11 | — | — | CN | disclosed |
| CN-1232511-C | Process for producing oxazolyl acetate derivative and salt thereof | JAPAN TOBACCO INC (JP) | 2005-12-21 | — | — | CN | disclosed |
| US-20050159466-A1 | PRODUCTION METHOD OF ISOXAZOLIDINEDIONE COMPOUND | JAPAN TOBACCO, INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005040127-A1 | NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2005-05-06 | — | — | WO | disclosed |
| CN-1511833-A | Method for producing isoxazolidinedione compound | �ձ��̲ݲ�ҵ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| CN-1495174-A | Method for producing isoxazolidinedione compound | �ձ��̲ݲ�ҵ��ʽ���� | 2004-05-12 | — | — | CN | disclosed |
| US-6699996-B2 | PRODUCING AN ISOXAZOLIDINEDIONE COMPOUND FROM BETA - METHYL L-ASPARTATE VIA AN IMPORTANT INTERMEDIATE OXAZOLYLETHANOL DERIVATIVE | JAPAN TOBACCO INC. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-0992503-B1 | PROCESS FOR PRODUCING ISOOXAZOLIDINEDIONE COMPOUND | JAPAN TOBACCO INC (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1384722-A1 | Process for the production of 2-(5-methyl-4-oxazolyl)acetates | JAPAN TOBACCO INC. (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1375499-A1 | Process for the production of 2-(5-methyl-4-oxazolyl)ethanol derivatives | JAPAN TOBACCO INC. (JP) | 2004-01-02 | — | — | EP | disclosed |
| CN-1130361-C | Method for producing isoxazolidinedione compound | JAPAN TOBACCO INC (JP) | 2003-12-10 | — | — | CN | disclosed |
| US-20020188133-A1 | Production method of isoxazolidinedione compound | JAPAN TOBACCO, INC. | 2002-12-12 | — | — | US | disclosed |
| US-6444827-B2 | FROM BETA-METHYL L-ASPARTATE VIA CHEMICAL INTERMEDIATE; EFFICIENCY; ANTIDIABETIC AGENTS | JAPAN TOBACCO INC. (JP) | 2002-09-03 | — | — | US | disclosed |
| US-20010039352-A1 | Production method of isoxazolidinedione compound | ANDO KOJI (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6248897-B1 | FROM BETA-METHYL L-ASPARTATE | JAPAN TOBACCO INC. (JP) | 2001-06-19 | — | — | US | disclosed |
| CN-1272109-A | Method for producing isoxazolidinedione compound | JAPAN TOBACCO INC (JP) | 2000-11-01 | — | — | CN | disclosed |
| EP-0992503-A1 | PROCESS FOR PRODUCING ISOOXAZOLIDINEDIONE COMPOUND | JAPAN TOBACCO INC. (JP) | 2000-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039352-A1 | Production method of isoxazolidinedione compound | DDO, GPR119, ALDH7A1 | KMT2A 382/4885MEN1 2371/4885POLB 2726/4885 |
| US-20020188133-A1 | Production method of isoxazolidinedione compound | DDO, GPR119, ALDH7A1 | KMT2A 382/4885MEN1 2371/4885POLB 2726/4885 |
| US-20050159466-A1 | PRODUCTION METHOD OF ISOXAZOLIDINEDIONE COMPOUND | GPR119, DDO, GABRD | KMT2A 387/4885MEN1 2576/4885POLB 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.